Report Overview

The European Colorectal cancer drugs market size stood at USD 4.24 billion in 2019 and is expected to rise to USD 5.78 billion by the end of 2028 exhibiting a CAGR of approximately 3.5% during the forecast period.

Colorectal cancer contributes to the sixth most common cause of deaths in Sweden. It is also the fourth most common cancer in Sweden, following Prostate, Breast and Lung cancers. According to the data from Globocan 2020, Incidence of Colorectal cancer cases amounted to 6.779 accounting for nearly 10.8% of all new cancer cases for both the sexes in the country.

Causes of colorectal cancer are mostly unspecified with certain environmental and genetic risk factors. The drugs market is anticipated to expand moderately during the forecast period. This is due to the progressive decline in the number of cases over the years. Owing to early and improved diagnostics and treatment methods, Sweden Colorectal cancer drugs market is brimming with new growth opportunities nonetheless.



Market Drivers

The rise in aging population is one of the major drivers of the Sweden Colorectal Cancer Drugs market. This is supported by increased per capita spending on healthcare and improved healthcare infrastructure in the country. Government initiatives to provide affordable care for the patients are also expected to drive the market. People have accepted the use of advanced therapies with newer drugs which further propel the market. Increasing awareness among the people about the disease and its consequences act as a market driver by paving way for early diagnosis and treatment.